Analysts Set Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Target Price at $55.00

Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) have been given a consensus rating of “Moderate Buy” by the five brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $55.00.

SLN has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Silence Therapeutics in a report on Tuesday, April 21st. HC Wainwright reissued a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a report on Friday, March 13th. Jefferies Financial Group raised shares of Silence Therapeutics to a “strong-buy” rating in a report on Wednesday, March 18th. Finally, William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a report on Monday, March 2nd.

Institutional Investors Weigh In On Silence Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE lifted its holdings in Silence Therapeutics by 903.8% in the 1st quarter. Bank of America Corp DE now owns 29,773 shares of the company’s stock valued at $157,000 after acquiring an additional 26,807 shares during the last quarter. Millennium Management LLC lifted its holdings in Silence Therapeutics by 50.3% in the 3rd quarter. Millennium Management LLC now owns 298,512 shares of the company’s stock valued at $1,549,000 after acquiring an additional 99,865 shares during the last quarter. Boothbay Fund Management LLC lifted its stake in Silence Therapeutics by 1.0% during the second quarter. Boothbay Fund Management LLC now owns 252,421 shares of the company’s stock valued at $1,464,000 after buying an additional 2,409 shares in the last quarter. Bank of Montreal Can lifted its stake in Silence Therapeutics by 4.4% during the fourth quarter. Bank of Montreal Can now owns 160,474 shares of the company’s stock valued at $976,000 after buying an additional 6,692 shares in the last quarter. Finally, Quadrature Capital Ltd purchased a new stake in Silence Therapeutics during the fourth quarter valued at about $331,000. 98.73% of the stock is owned by institutional investors and hedge funds.

Silence Therapeutics Stock Up 0.6%

SLN stock opened at $6.90 on Friday. The company has a market capitalization of $325.96 million, a P/E ratio of -4.34 and a beta of 1.52. The company has a 50-day simple moving average of $6.52 and a 200 day simple moving average of $6.11. Silence Therapeutics has a fifty-two week low of $4.19 and a fifty-two week high of $8.40.

Silence Therapeutics (NASDAQ:SLN) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.14). The company had revenue of $0.42 million during the quarter, compared to analyst estimates of $1.26 million. Silence Therapeutics had a negative return on equity of 105.34% and a negative net margin of 8,943.86%. Equities analysts anticipate that Silence Therapeutics will post -1 EPS for the current year.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.